← Human Trials & Peer-Reviewed Studies
Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial
Plain-language guide to PMID 23359039 (2013): crossover randomized controlled trial study of Insulin Aspart and Glucagon in 15 adults.
Key Facts
- PMID
- 23359039
- Journal
- CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Haidar A et al. (10 authors)
- DOI
- 10.1503/cmaj.121265
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Insulin Aspart and Glucagon.
Most patients with type 1 diabetes do not achieve their glycemic targets.
Who Took Part
The study group was 15 adults.
PubMed indexes the participants as adults, both men and women.
The researchers conducted a randomized crossover trial involving 15 adults with type 1 diabetes, comparing standard insulin-pump therapy with dual-hormone, closed-loop delivery.
Patients were admitted twice to a clinical research facility and received, in random order, both treatments.
How the Study Was Run
The design is described as randomized and crossover.
Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.
Each person switched between Insulin Aspart and the comparison at some point, usually with a gap in between.
Each 15-hour visit (from 1600 to 0700) included an evening exercise session, followed by a medium-sized meal, a bedtime snack and an overnight stay.
During visits involving standard insulin-pump therapy (control visits), patients used conventional treatment.
What Was Measured
Topics PubMed links to this paper include Algorithms, Biomarkers, Blood Glucose, Decision Support Techniques, Diabetes Mellitus, Type 1, Glucagon and Hypoglycemia.
What This Means in Plain Language
The paper is a randomized and crossover study of Insulin Aspart and Glucagon in 15 adults.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2013 (CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne), a journal based in Canada.
More context: the Insulin Aspart compound page and the Glucagon compound page, all human trials.
Our Notes on the Compounds
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.